Pennsylvania Department of Health Awards Jefferson $3.5 Million from Tobacco Settlement Funds to Establish a New Center of Excellence on Neurodegenerative Dise

LA JOLLA, Calif. A member of the National Academy of Sciences since 1977, Dr.

vasculitis neurological

The researchers plan,
for example, to test innovative screening methods to better identify dementia
in a racially and economically diverse population. Gandy. Rovner to both develop and
validate the screening tool. Gitlin, director of the Center for Applied Research on Aging and
Health, and professor in the Department of Occupational Therapy at the
Jefferson College of Health Professions at Thomas Jefferson University, will
direct the randomized trial of the home-based skills training program for
caregivers. They
will be working closely with the Philadelphia Corporation for Aging (PCA). "We look forward to Floyd's continuing
contributions to neuroscience, both at the Institute and through the promising
work of Neurome."

About The Scripps Research Institute
The Scripps Research Institute in La Jolla, California, and Palm Beach
County, Florida, is one of the world's largest, private, non-profit biomedical
research organizations.

parenchyma meninges

"Making a diagnosis as soon as possible
is important now because there are clinical trials for drugs aimed at the
early stages of disease," Dr. "We need people to be diagnosed
early to have the best chances of responding . in 2001.D.

hyperventilation dysautonomia

D.
Alzheimer's and related disorders cost an average of $80,000 a year per
patient , and $25 million per year overall in Pennsylvania.
Barry Rovner, M., and The
Scripps Research Institute today announced Dr. Bloom's more than
600 publications include the seminal work: The Biochemical Basis of
Neuropharmacology.

g.

dysautonomia amyotrophic

5-million
grant from the Pennsylvania Department of Health to support a Center of
Excellence on Neurodegenerative Diseases at the Farber Institute for
Neurosciences at Thomas Jefferson University in Philadelphia. Gandy, director of the
Farber Institute for Neurosciences and professor of neurology and biochemistry
and molecular pharmacology at Jefferson Medical College of Thomas Jefferson
University."
Alzheimer's disease is a major public health cost for the nation and
particularly for Pennsylvania, which has a large elderly population. They are looking for markers of disease risk and stress in both
patient and caregiver at two different points in the program.
"This project represents our growing understanding of the disease and
mobilizing the health-care and academic systems to tackle the problem," Dr.

neoplasms amyotrophic

On the biological side, the researchers are developing a database of
ethnically diverse individuals, with special emphasis on the African-American
population. Bloom will be named
Professor Emeritus at Scripps Research and also intends to devote substantial
efforts to the work of Neurome, Inc. Please visit the
Institute at http://www.

About Neurome

Neurome, Inc.

delirium neurotoxicity

, director of Clinical Alzheimer's Disease Research at
the Farber Institute for Neurosciences at Thomas Jefferson University and
professor of psychiatry and neurology at Jefferson Medical College, will
direct the development and testing of the diagnostic tool., director of geriatric medicine in
the Department of Family Medicine at Jefferson Medical College of Thomas
Jefferson University, who is working with Dr.
Farber Institute for Neurosciences at Thomas Jefferson University is a
multidisciplinary neurosciences research center established through a $10
million gift by the Farber Family Foundation, Inc. It is initially
focusing its efforts on basic and clinical research in a number of key areas,
including Alzheimer's disease , Parkinson's disease, amyotrophic lateral
sclerosis (ALS) and other neurodegenerative disorders.

ataxia vasculitis

, will work in collaboration with the Philadelphia Corporation
for Aging, in order to conduct several research projects, each focusing on a
different aspect of the Alzheimer's disease equation. Gandy says. It stands at the forefront of basic biomedical
science that seeks to comprehend the most fundamental processes of life.

syndromes neurotoxicity

D.

Floyd Bloom to Retire as Scripps Research Department Chair; Focus on Neurome Neurodegeneration Programs

is a discovery stage biotechnology company that seeks
therapeutic solutions to human neurodegenerative diseases.

Sites dealing with strictly medical aspects of neurological diseases (e.

sites intended for healthcare providers) should be submitted to Health/Medicine/Medical Specialties /Neurology instead of this category.

demyelinating delirium

Individuals will be referred for participation in the study to receive either
the innovative treatment or educational materials.

chromosomal motility

Since its founding in 2000 , Neurome has developed and optimized
proprietary technologies to reveal and quantify gene expression patterns and
the resultant morphological details of brain structures in normal and
pathological brains with an unprecedented level of sensitivity, specificity
and resolution.

neoplasms neurologic

Bloom, M.

autonomic hemiplegia

Lerner, M.

demyelinating chorea

Neurome's unique technologies to measure and assess
neurodegenerative processes at work -- at the molecular, cellular and
macroscopic levels -- are ideally suited to identify the earliest evidence of
pathology in models of human diseases of the Central Nervous System, as well
as to evaluate the comparative effectiveness of pharmaceutical candidates for
intervention.

neurological neurocutaneous

The costs will rise
to an estimated $40 million a year by 2050. Building on her previous work in this area, she plans to test
whether such a program can help reduce troublesome behaviors in Alzheimer's
patients by teaching families problem-solving skills, how to engage the
patient in meaningful activities and minimize triggers of behaviors and at the
same time manage their own stress.
"An innovative feature of this randomized controlled trial is that the
intervention will be tested in a real community setting so that if it is
effective, it can easily be translated into the aging network," she says . Bloom has served as Chairman of the
Department of Neuropharmacology from 1989 to 2000 and again from 2002 to the
present.

hyperventilation dysautonomia

The health
research grant is awarded from Pennsylvania's share of the national tobacco
settlement.D.
"The disease goes on for five to 15 years of intense stress for the
family, especially the primary caregiver," says Dr. He and his group
are developing a new screening tool combining cognitive tests assessing
patient memory, orientation, language, and other abilities with a
questionnaire given to family members., the La Jolla-based biotechnology company
dedicated to discovery and development of solutions for human
neurodegenerative diseases, which he co-founded in 2000. He has also been named a member of the Royal Swedish Academy
of Sciences and a member of the Institute of Medicine. The company dedicates these technologies to discovery and
development of drugs to provide effective treatments for diseases
characterized by neurodegeneration .

dysautonomia syndromes

"The unique aspect of this project is the focus on developing a convenient
diagnostic test that many caregivers and case workers can administer, and on
training caregivers in non-drug related strategies that can help keep patients
at home longer prior to nursing home placement," says Dr.

"
"Our sense is that Alzheimer's may be under-recognized in some
communities," says Christine Arenson, M.

vasculitis delirium

Sam
Gandy, M.D., PH.D. They also are going to
examine the effectiveness of an in-home skills training program for caregivers
to see if it can help delay patients from going to nursing homes, and at the
same time, help reduce the stress on the caregiver. Bloom's retirement as chairman
of the Scripps Research Department of Neuropharmacology. Bloom is the immediate past Editor-in-Chief of Science, the world's
premier journal of scientific thought and discovery, and served as President
of the American Association for the Advancement of Science from 2002 to 2003 ,
and as Chairman of the Board of Directors, from 2003 to 2004. A professor at
Scripps Research since 1983, Dr."
"In a career blessed by association with remarkable investigators, I've
had no pleasure greater than the fellowship of my Scripps Research
colleagues," said Bloom.edu.

ataxia syndromes

is principal investigator of a four-year, $3. "Available medications are inadequate, making it imperative that
caregivers be trained in how best to create an environment conducive to the
care of someone with Alzheimer's . My continuing associations with Scripps Research and with my
colleagues at Neurome, will be dedicated to the challenge of making that
promise a reality through development of understanding and treatment of human
neurodegenerative disease.

motility syndromes

New Jefferson State Grant Focused on Early Detection, Prevention of
Alzheimer's and Caregiver Relief

PHILADELPHIA, How can a family tell if a loved
one is in the beginning stages of Alzheimer's disease? Are there changes
individuals can make in their lifestyle to reduce or perhaps delay the effects
of the disease? What can caregivers do to lessen their burden?
These are some of the questions Jefferson investigators hope to answer ., and Laura
Gitlin, PH.
Dr. Gitlin and her colleagues are developing a "risk screen" that PCA care
managers will use to identify family caregivers who are at risk for placing
their family member in a nursing home and who might benefit from the research.
"Floyd Bloom has distinguished our faculty and American science with his
unique combination of experimental vision, intellectual integrity,
investigative energy and generous collegiality," said Scripps Research
President Richard A. "Under Richard Lerner's leadership, the Institute
has pioneered a new neuroscience and articulated the promise of a new
medicine.
Scripps Research is internationally recognized for its research in immunology,
molecular and cellular biology, chemistry, neurosciences, autoimmune diseases,
cardiovascular diseases and synthetic vaccine development.com.

motility amyotrophic

The new Jefferson center, co-directed by Barry Rovner, M.D.
Dr.
Gandy says., Floyd E. The company
focuses its efforts on Alzheimer's disease, Parkinson's disease, Huntington's
disease, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) --
usually fatal neurodegenerative disorders that are currently untreatable and
share characteristics which make them particularly amenable to Neurome's
expertise and technologies .

neoplasms hyperventilation

Dr.scripps.

porencephaly neurotoxicity

The researchers would also like to identify lifestyle factors in the
development of Alzheimer's, and how modifying them - changing dietary
cholesterol, for example - might affect the course of the disease, in addition
to measuring objective biological markers of stress and of disease risk, such
as the buildup of sticky amyloid in the brain. Bloom
is the recipient of numerous prizes for his contributions to science,
including the Janssen Award in the Basic Sciences and the Pasarow Award in
Neuropsychiatry.neurome.

chorea dysautonomia

Dr.D. Detailed information on the Neurome
technologies and the scientific and medical challenges of human
neurodegenerative disorders are available at Neurome 's website:
http://www.

neurologic neurotoxicity

Health/Conditions and Diseases/Neurological Diseases deals with the health aspects of neurological problems.

syndromes neurocutaneous

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)